Asthma Rx Deemed Less Likely to Work in Patients Aged 30 and Up

Share this content:
Asthma Rx Deemed Less Likely to Work in Patients Aged 30 and Up
Asthma Rx Deemed Less Likely to Work in Patients Aged 30 and Up

(HealthDay News) -- Asthma treatments, especially inhaled corticosteroids, are less likely to work for older patients, according to a study published online June 11 in the American Journal of Respiratory and Critical Care Medicine.

Researchers looked at 1,200 patients with mild-to-moderate asthma, and found that treatment failure occurred in 17.3 percent of those aged 30 and older, compared with 10.3 percent of those younger than 30.

Lower lung function and having asthma for a longer time were associated with a higher risk of treatment failure. When the researchers focused on specific therapies, they found that treatment failure increased consistently for every year above age 30 among patients who used inhaled corticosteroids. Patients aged 30 and older who used inhaled corticosteroids, either alone or in combination with other therapies, were more than twice as likely to have treatment failure than those younger than 30, the investigators found. Men and women had similar rates of treatment failure.

The finding that older asthma patients are at increased risk for treatment failure "may involve not only biological mechanisms, such as differences in the type of airway inflammation in older patients, but may also involve socioeconomic, geographic, or treatment adherence differences between older and younger patients," study coauthor Ryan Dunn, M.D., of National Jewish Health in Denver, said in a journal news release. "Further research is needed to elucidate the causes underlying our observations and to examine whether older patients might benefit from a unique treatment approach."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »